Long QT Syndrome Diagnosis and Management

Diagnosis and Screening

The American College of Cardiology recommends genetic counseling and mutation-specific genetic testing for first-degree relatives of patients with a causative mutation for long QT syndrome (LQTS) 1
LQTS diagnosis should be considered when QTc ≥480 ms in repeated 12-lead ECGs or QTc ≥460 ms with unexplained syncope, according to the European Heart Journal 2
A 12-lead ECG with careful QT measurement is essential for diagnosis, and exercise treadmill testing can be useful for diagnosing LQTS in patients with borderline QTc intervals, as recommended by the American College of Cardiology 1
Ambulatory ECG monitoring and ECG recording while lying and immediately upon standing can also be helpful in diagnosis, according to the American College of Cardiology 1
Genetic testing can identify disease-causing mutations in 50-86% of LQTS phenotype-positive patients, with a higher yield in patients with marked QT prolongation or positive sudden cardiac arrest, as reported by the American College of Cardiology 1
The most common genes associated with LQTS are KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3), accounting for 90% of genotype-positive cases, according to the European Heart Journal 2

Patients with QTc >500 ms, prior syncope or cardiac arrest, and certain genotypes (LQT1, LQT2, LQT3) are at higher risk, as reported by the American College of Cardiology and the European Heart Journal 1, 2
Female sex, especially postpartum for LQT2, and age (highest risk in first 3 decades of life) are also risk factors, according to the American College of Cardiology and the European Heart Journal 1, 2

Lifestyle modifications, such as avoiding QT-prolonging medications and correcting electrolyte abnormalities, are recommended by the American College of Cardiology and the European Heart Journal 1, 2
Beta-blockers are recommended for all patients with clinical diagnosis of LQTS, patients with QTc >470 ms, and carriers of causative LQTS mutation with normal QT interval, as reported by the American College of Cardiology and the European Heart Journal 1, 2
ICD implantation is recommended for LQTS patients with previous cardiac arrest, LQTS with sudden cardiac arrest if meaningful survival >1 year expected, and patients who experienced syncope/VT while on adequate beta-blocker dose, according to the American College of Cardiology and the European Heart Journal 1, 2

Regular ECG monitoring with QTc measurement and exercise testing to assess beta-blocker efficacy are essential, as recommended by the American College of Cardiology 1
Documenting QTc before initiating QT-prolonging drugs and at least every 8 hours thereafter is crucial, according to Praxis Medical Insights 3
Consideration of dose reduction or discontinuation if QTc increases by >60 ms from baseline or reaches >500 ms is necessary, as reported by Praxis Medical Insights 3